John Valliant, PhD
Chief Executive Officer
Senior Director, Finance & Administration
Vice President, Quality Operations
Director, Manufacturing Operations
Chief Regulatory Officer
Vice President, Operations
Dr. John Valliant is the founder of CPDC. Dr. Valliant oversees the strategic directions of the scientific and commercial programs of the CPDC, to ensure the Centre’s long-term vision and sustainability.
John is currently Professor in the Department of Chemistry and Chemical Biology, at McMaster University. He is recognized internationally for his work in radiopharmaceutical chemistry. His current research focuses on developing novel radiolabeling methods and compound discovery strategies, in order to create clinically relevant imaging and therapeutic drug candidates. Thus far, John has published more than 100 peer review research papers and holds 16 patents in the area of radiochemistry and radiopharmaceuticals. He completed his PhD at McMaster University, followed by a post-doctoral fellowship under the joint supervision of professors Alun G. Jones (Harvard) and Alan Davison (MIT).
John was selected as one of ‘Canada’s Top 40 Under 40’ in 2009, a distinction that recognized his exceptional work to advance radiopharmaceutical technology and education, improve patient care, and generate economic growth, through his work at the CPDC and McMaster University. More recently he was a co-recipient of the Brockhouse Prize for Interdisciplinary Research in Science and Engineering (2015).
Bruno Paquin joined CPDC in November 2018 as the Director, Business Development, and since December 2019, as the Senior Director, Business Development. In this role, Bruno oversees all the business development activities including management of the service contracts, collaboration and licensing agreements for CPDC. Bruno also manages business development activities for CanProbe, a startup in the field of molecular imaging and theranostics founded by CPDC and the University Health Network (UHN). Effective March 2021, Bruno assumed the role of CEO for CPDC, in addition to his current role as Sr. Director of Business Development.
Bruno received his PhD in Biochemistry from Université de Montréal before conducting his post-doctoral research at the University at Albany, NY. He became the Laboratory Director at Université de Montréal, Département de Biochimie, where he was responsible for the management and direction of a team of scientists. In 2000, he became the head of the Technology Development Unit at Genizon Biosciences Inc., where he transitioned to business development and was appointed the Executive Director, Head of Business Development. Bruno then went on to become VP of Business Development for Immuni T in Montréal in 2011 until he joined CPDC. While at CPDC, Bruno was appointed to the CanProbe board of Directors and currently serves as the President.
Angela Lauretani joined CPDC in July 2015 as the Finance Controller and transitioned into her current role as Senior Director, Finance and Administration in February 2018. In her current role, Ms. Lauretani is responsible for the Finance operations of CPDC, including grant reporting, budgeting and commercialization efforts. She also oversees the IT and Administration departments.
Angela has over 15 years of experience in financial management, previously employed by a publicly traded company (NYSE) for 10 years and began her professional career in public accounting with KPMG, where she obtained her Chartered Accountant, CPA designation. Angela holds an Honours Bachelor of Commerce from McMaster University.
Oscar Grilli joined CPDC in 2019 as Quality Assurance Director. He had then the responsibility to support the hosting of an FDA inspection and the re-organization and staffing of the QA department. In his current role, Oscar oversees the quality assurance, quality control, sterility assurance, and analytical development departments. He leads his team towards ensuring compliance, championing continuous improvement initiatives, and supporting the daily manufacturing operations.
Oscar has more than 20 years of experience in Quality functions, mostly developed in multinational pharmaceutical companies, focused on quality assurance, aseptic processing, SPC, and validation functions. He has developed and implemented validation programs for existing and new facilities, routine monitoring programs, training programs, improvement initiatives, and hosted regulatory inspections.
His experience also includes the management of Operations, QC, QA, and Sterility assurance teams.
Oscar holds a bachelor degree in Chemical Engineering, and an Ontario’s engineer professional license.
Constantinos Economou joined CPDC in June 2010 as a Cyclotron Engineer and transitioned into his current role as Director, Manufacturing Operations in September 2017. In his role, Mr. Economou is responsible for the Manufacturing Operations across the CPDC network.
Constantinos has over 20 years of experience in manufacturing. Prior to joining CPDC in 2010, Constantinos spent 11 years in the automotive sector in various Engineering roles. Constantinos is a Professional Engineer and holds a Bachelor’s Honours Degree in Mechanical Engineering as well as a Master’s of Science in Advanced Manufacturing from the University of Salford, Manchester, UK.
Anne Goodbody joined the CPDC in 2008 and oversees CPDC’s regulatory functions, clinical operations and translational research. At CPDC she has successfully led the development of radiopharmaceuticals, covering early stage development through to market authorization.
Anne has over 25 years of pharmaceutical research and development experience. Prior to joining the CPDC, she was the VP Drug Development at Vasogen Inc., where she managed the company’s drug development program. In previous positions as VP of Development at Molecular Insight Pharmaceuticals and Director of Development at Resolution Pharmaceuticals, she ran successful radiopharmaceutical development programs. She has also worked in research and development at Allelix Inc. and Bayer.
Anne holds a PhD in biochemistry from the University of Cambridge (UK), has published extensively and is a named inventor on 15 issued patents.
Anton Knezovic joined CPDC in 2018 as Director Human Resources and in early 2019 assumed additional responsibility as the Delivery Team Lead for a new facility spin off. In his role, Mr. Knezovic is responsible for strategic implementation and execution of all Human Resources objectives to assure organizational success across the CPDC network.
Mr. Knezovic has over 12 years of experience in the human resources profession. Prior to joining CPDC in 2018, Mr. Knezovic spent a vast majority of his career in the manufacturing and pharmaceutical industries focusing on organizational development, employee and labour relations, talent acquisition and full cycle talent management. Mr. Knezovic holds a Bachelor’s Degree in Science, Biology as well as a post graduate Diploma in Human Resource Management.
CPDC is governed by an independent Board of Directors. Board members represent all key sectors associated with the CPDC. The Board of Directors works with the CEO and CPDC executive team to shape the CPDC’s future direction and success.
John ThornbackChair of the CPDC Board of Directors
Gay YuyitungVice-Chair of the CPDC Board of Directors
Stewart FastSenior Program Manager, Networks of Centres of Excellence
Karen GulenchynNuclear Medicine Physician, Hamilton Hospitals and Cambridge Memorial Hospital
Damian LambManaging Director, Genesys Capital
Mark LundieDirector, Medical Affairs, Rare Diseases Pfizer Canada Inc.
Bruno PaquinCEO, CPDC
Jean-Claude ProvostManaging Partner at Theranostics Consulting
Paul SchafferAssociate Laboratory Director, Life Science TRIUMF
Robert SutherlandDirector, CPDC
John ValliantFounder, CPDC Principal Investigator
Annick Van den AbbeelePresident-Elect, International Cancer Imaging Society
Hamilton, Ontario, February 24, 2021 – The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, is announcing today that the first patient has been dosed and imaged in a Phase 3 trial for [18F]PSMA-1007. This diagnostic imaging product is a positron-emitting tomography (PET) agent that
CPDC’s Discovery Team is experienced in oncology, immuno-oncology, and neurology models.
CPDC and University Health Network have created a joint venture, CanProbe, to accelerate the clinical development of molecular imaging probes.
CPDC’s manufacturing facilities are approved by Health Canada for the production of positron emitting radiopharmaceuticals.
Global drug companies are using CPDC’s know-how and world-class facilities to develop and test new drugs and molecular probes.
During medical isotope shortages, CPDC can provide substitutes for use in bone scans and imaging kidney function.
CPDC can create PET and SPECT imaging companions for small molecules, peptides, antibodies and other biologics.
CPDC works with all therapeutic and diagnostic isotopes, and has extensive expertise with alpha and beta emitting nuclides.
Cyclotrons can be used to produce enough Tc-99m within 6 hours to enable over 500 nuclear imaging scans.
Molecular imaging probes can show a tumour’s biochemical response to treatment in just a few days, unlike conventional modes like MRI or CT, which may not show a change in tumour size for several weeks.
ARTMS Products Inc. has been created by Triumf, BCCA, LHRI and CPDC to commercialize jointly-developed technology for production of Tc-99m on standard medical cyclotrons.
Molecular PET imaging probes are used primarily to diagnose cancer, heart disease and neurological conditions.